Dr. Khosravi-Far of InnoTech Precision Medicine

InnoTech Precision Medicine is developing an integrated multiomics diagnostic platform with AI-decision support designed for rapid, accurate, and non-invasive disease detection at the point of care. The system incorporates lab-on-a-chip technology and a proprietary cartridge that automates sample preparation, nucleic acid amplification, and multiplexed optical biomarker detection. By simultaneously analyzing genomic, transcriptomic, proteomic, and epigenomic signatures from saliva or blood, the platform generates a multi layered molecular profile in a single test, eliminating the need for centralized laboratory infrastructure.

AI-driven analytics further enhance diagnostic performance by refining signal processing, biomarker pattern recognition, and disease risk stratification. Cloud-enabled data interpretation provides real-time support for clinical decision-making. The initial application focuses on HPV-driven oropharyngeal squamous cell carcinoma (OPSCC), addressing the limitations of current early detection methods.

The modular design enables broader applications in oncology, infectious disease, and chronic disease monitoring. Its portability also supports hospital-at-home and telehealth use cases, where rapid patient-side molecular testing is essential for timely intervention. Compared to single-biomarker or single-modality assays, the multiomics approach offers improved sensitivity, specificity, and predictive accuracy while enabling equitable access to saliva-based diagnostics for underserved populations. Supported by NIH, NSF, and other non-dilutive funding, this platform provides a scalable pathway toward accessible and clinically actionable precision diagnostics.

Biography:

Dr. Roya Khosravi-Far is the Chief Executive Officer and Co-Founder of InnoTech Precision Medicine. She is a former Professor at Harvard Medical School with over 30 years of experience in oncology, molecular biology, and translational medicine. Her research career has focused on the molecular mechanisms of cancer progression and therapeutic resistance, leading to numerous peer-reviewed publications and patents. At InnoTech, she leads the development of rapid, AI-enabled, multiomics diagnostic platforms that integrate plug-and-play chemistry with lab-on-a-chip technology for accessible, point-of-care testing.

Dr. Khosravi-Far has extensive expertise in precision medicine, cancer biology, and innovation in diagnostics. She has served as a mentor to early-career scientists and entrepreneurs and is committed to advancing equitable healthcare by bringing high performance diagnostics into community and home settings. Under her leadership, InnoTech has secured support from the NIH, NSF, CDC, Massachusetts Life Sciences Center (MLSC), and other non-dilutive funding organizations, positioning the company to redefine early disease detection and improve patient outcomes worldwide.